We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Vircell S.L.

Vircell is a biotechnology company specializing in the development and production of ready-to-use reagents for the di... read more Featured Products: More products

Download Mobile App





Vircell Exhibits Its New VirClia Lotus and qSPEED-OLIGO Systems at MEDLAB

By LabMedica International staff writers
Posted on 05 Feb 2020
Vircell (Granada, Spain) exhibited its new instruments, VirClia Lotus and qSPEED-OLIGO, at MEDLAB Middle East, an event for showcasing the latest technology and knowledge in the IVD and medical laboratory market that was held at the Dubai International Convention and Exhibition Centre from February 3-6, 2020.

Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. More...
It is specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology.

At this year’s MEDLAB Middle East, Vircell exhibited VirClia Lotus, its new Chemiluminescence system (CLIA) designed to process diagnostic immunoassays VirClia Monotest. The VirClia Lotus CLIA system offers random access with continuous loading, STAT function to manage urgent samples, and positive identification of samples and strips through an internal scanner. It delivers the firsts results in one hour (new result every 30 seconds), 40 tests in one hour 25 minutes, and 80 tests in two hours 30 minutes with a capacity of 50 primary tubes and/or aliquots.

Vircell also presented its new approach on molecular biology, the qSPEED-OLIGO which is a unique molecular diagnostic tool for real-time PCR multiplex testing of infectious diseases and offers automated identification of positive samples. The qSPEED-OLIGO system includes a two-channel fluorescence thermocycler which allows for the screening of all pathogens (FAM) and for the internal control and sample validation (HEX). It helps rapidly discard negatives and focus only on identifying positive samples. The benchtop modular instrument increases laboratory throughput with automated screening of 48 samples in less than 90 minutes. It provides the advantage of minimum hands-on-time protocol by using pre-dispensed qPCR tubes and sealed cassettes to rule out contamination.

Related Links:
Vircell


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.